Tech Company Financing Transactions
Zhiyi Biotech Funding Round
Zhiyi Biotech closed a $45 million Series B venture capital round on 7/7/2022. Investors included Korea Investment Partners, SDIC Fund Management and private investors.
Transaction Overview
Company Name
Announced On
7/7/2022
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series B
Investors
Korea Investment Partners (Lead Investor)
SDIC Fund Management (Lead Investor)
Proceeds Purpose
The company intends to use the funds to boost the clinical development of the its live biotherapeutic products (LBPs) pipelines.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3rd Floor Building A No.2 Ruitai Road High-tech Industrial D
Guangzhou Guangdong, Undisclosed
China
Guangzhou Guangdong, Undisclosed
China
Phone
Website
Email Address
Overview
Zhiyi is a leading company in live biotherapeutics (LBPs) and next-generation probiotics in China. The company's SK08(Bacteroides fragilis) was approved for clinical trials in November 2019.It is the first LBP in China with immense influence.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ye Wang
Browse more venture capital transactions:
Prev: 7/7/2022: Traba venture capital transaction
Next: 7/7/2022: Biosyntia venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs